Treatment of pulmonary arterial hypertension;Behandlung der Pulmonal Arteriellen Hypertonie

Pneumologie

Volumn 54, Issue 6, 2000, Pages 222-224

  Olschewski, H ^a   Seeger, W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; NITRIC OXIDE;

EID: 0033947730     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-3823     Document Type: Editorial

References (24)

1. 1 Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415
2. 2 Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301
3. 3 Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996; 109: 1545-1549
4. 4 Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. The influence of continous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transpl 1998; 17: 679-685
5. 5 De Jaegere APMC, van den Anker JN. Endotracheal instillation of prostacyclin in preterm infants with persistant pulmonary hypertension. Eur Respir J 1998; 12: 932-934
6. 6 Eichelbronner O, Reinelt H, Wiedeck H, Mezody M, Roissant R, Georgieff M et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock - different effects on splanchnic oxygenation?. Intensive Care Med 1996; 22: 880-887
7. 7 Higenbottam TW, Butt AY, DinhXuan AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79: 175-179
8. 8 Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155
9. 9 McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277
10. 10 Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349: 1365
11. 11 Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824
12. 12 Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbrück B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998; 24: 631-634
13. 13 Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbrück B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2): 600-607
14. 14 Olschewski H, Ghofrani HA, Winkler J, Wilkens H, Höper MM, Behr J, Kleber F-X, Seeger W and the German PPH Study Group. Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial.Ann Intern Med 2000; 132: 435-443
15. 15 Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Care Med 1998; 157: 1743-1747
16. 16 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81
17. 17 Robbins I, Christman BW, Newman JH, Matlock R, Loyd JE. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998; 114: 1269-1275
18. 18 Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244-247
19. 19 Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Resp J 1998; 12: 265-270
20. 20 Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolized prostacyclin in adult respiratory distress syndrom. Lancet 1993; 342: 961-962
21. 21 Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 1995; 151: 724-730
22. 22 Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 991-996
23. 1 for severe idiopathic pulmonary hypertension. N Engl J Med 1980; 306: 1326-1331
24. 24 Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratoy distress syndrome. Am J Respir Crit Care Med 1996; 154: 1671-1677